The subscription period ended in Q1 2021. The rights issue was subscribed to a total of approximately 268 percent by existing shareholders and the public. Stayble will thus receive approximately SEK 41.5 million before transaction related costs. The capital that the company is now provided is intended to finance the Company's operations until completion and processing of the results from the Company's ongoing clinical Phase 2b trial.

Read more about the Rights Issue

Latest press releases

16 August 2021 Regulatory

Stayble Therapeutics AB offentliggör kvartalsrapport för Q2 2021

Göteborg, 16 augusti 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för andra kvartalet (april– juni) 2021...

02 June 2021 Regulatory

(SE) Kommuniké från årsstämma i Stayble Therapeutics den 2 juni 2021

Idag, den 2 juni 2021, hölls årsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet....

Bridging the therapeutic gap

About 30% of all patients with discogenic cLBP are helped by therapy such as analgesics and physiotherapy, and only 1% undergo spine surgery. Stayble’s product STA363 will bridge the gap between conservative and radical therapy to the benefit of millions of patients presently left on their own to cope with sustained and disabling pain.

Our market

Treating the root cause of the disease. Not just the symptoms.

Instead of costly or time-consuming procedures, such as spinal fusion or long-term physiotherapy, our cLBP treatment is an easily performed, single injection procedure that stabilises the disc by transforming it to connective tissue. Unlike any other currently available treatment, this has the potential to permanently attenuate the pain significantly faster than surgical intervention.

Healthy disc

An intervertebral disc consists of two main parts: the disc centre and the wall. The disc centre consists largely of a highly hydrated gel together with nucleus pulposus cells and fibroblasts.


When a disc degenerates it becomes less stable and proinflammatory substances formed during the degenerative process can leak from the inner core of the disc. Pain-sensing nerves within and outside the wall of the disc are activated. These processes cause back pain.

Treated disc

By injecting STA363 directly into the degenerated intervertebral disc, the cells are triggered to produce collagen and the damaged disc is transformed into connective tissue. This helps restabilise the intervertebral segment and reduces leakage of proinflammatory substances.

Read more


We are participating in several conferences and industry events every year. Please do not hesitate to contact us to meet up.

Upcoming events

No events planned at the moment

Upcoming events

Get in touch

We are always looking for passionate people who are interested in joining us to help realizing our vision. Please leave your contact details and we will get back to you shortly.